Injectable Drug Delivery Device Market Rising Demand Of Self-Injection Devices 2018-Dominated By Baxter International, Becton Dickinson, Gerresheimer, Pfizer, SCHOTT AG, Teva Pharmaceutical Industries And Others-Forecast 2025

Injectable drug delivery is the delivery of drugs, medicines or pharmaceutical compound into the body via blood stream for a therapeutic effect. This drug delivery is the second-most important class of drug delivery after oral drugs. The technique includes many technologies, formulations and modes of administration to attain the preferred physiological effects.

Avail 10% Discount on Direct Purchase "Global Injectable Drug Delivery Market" Or kindly send the email @ Sales@databridgemarketresearch.com

The injectable drugs enter directly into the blood and show an immediate action, accurate result, less side effects, faster action, high efficacy, ability of administering drugs in comatose and unconscious patients, and provide immediate relief from chronic pain such as cancer, diabetes, cardiovascular. Also, injections can offer severe pain relief to the exact area by providing an effective result.

Click Here For Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market

In recent years, the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others) has increased significantly over a period of time worldwide. The rapidly increasing aging population and the following rise in chronic conditions are major factors driving the demand for healthcare. This increase in prevalence of chronic diseases has resulted in a significant increase in the demand for self-injectable as these devices are more convenient and safe to use at home. According to World Health Organization, in 2014, the prevalence of diabetes over the age of 18 years has increased to 8.5%. According to National Cancer Institute, cancer is considered as one of the leading causes of death globally. Around 8.8 million cancer-related deaths were reported in 2015 around the globe.

Market Segmentation: Global Injectable Drug Delivery Market

The global market for injectable drug delivery by the following sub-categories is presented

By Type
Injectable Drug Delivery Devices
Conventional Injection Devices
Self-Injection Devices
Needle Free Injectors (NFI)
Auto Injectors
Pen Injectors
Wearable Injectors
Injectable Drug Delivery Formulation
Conventional Drug Delivery Formulations
Solutions
Reconstituted/Lyophilized
Suspensions
Emulsions
Novel Drug Delivery Formulations
Colloidal Dispersions
Microparticles
Long Acting Injection Formulation

By Application
Hormonal Disorders
Injectable Drugs For Diabetes
Injectable Drugs For
Injectable Drugs For Reproductive Health Disease
Injectable Drugs For Antithrombotic/Thrombolytic Therapy
Injectable Drugs For Osteoporosis
Injectable Drugs For Growth Hormone Disorders (GHD)
Oncology
Autoimmune Diseases
Injectable Drugs For Rheumatoid Arthritis
Injectable Drugs For Multiple Sclerosis
Injectable Drugs For Crohn’s Diseases
Injectable Drugs For Psoriasis
Injectable Drugs For Other Autoimmune Diseases
Orphan Disease
Other Applications
Injectable Drugs For Pain Management
Injectable Drugs For Allergy Treatment
Injectable Drugs For Aesthetic Treatments
Injectable Drugs For Hepatitis C
Injectable Drugs For Hemophilia

By Usage Pattern
Curative Care
Immunizations
Others
By Mode Of Administration
Skin, Circulatory/ Muskoskeletal
Organs
Central Nervous System

By End User
Hospitals And Clinics
Home Healthcare Settings
Research Laboratories
Pharmaceutical and Biotechnological Companies
Others

By Distribution Channel
Hospital Pharmacy
Pharmacy Stores
Direct Tender
Online Pharmacy

By Geography
North America
Europe
Asia-Pacific
South America
Middle East and Africa

Any Specific Requirements? Questions? Ask to Our Industry Expert @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market

TABLE OF CONTENTS GLOBAL INJECTABLE DRUG DELIVERY MARKET
1. INTRODUCTION

1.1. OVERVIEW OF GLOBAL INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET

3.2. RESTRAINTS

3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK
3.3. OPPORTUNITY
3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS
3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS

3.4. CHALLENGES

3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY

6.1. OVERVIEW

6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)

7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE

7.1. OVERVIEW

7.2. INJECTABLE DRUG DELIVERY DEVICES

7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS

7.3. INJECTABLE DRUG DELIVERY FORMULATION

7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS

7.3.2. NOVEL DRUG DELIVERY FORMULATIONS

7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION

8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

8.1. OVERVIEW
8.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.3. HORMONAL DISORDERS

8.3.1. INJECTABLE DRUGS FOR DIABETES
8.3.2. INJECTABLE DRUGS FOR ANEMIA
8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)

8.4. ONCOLOGY
8.5. AUTOIMMUNE DISEASES

8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTABLE DRUGS FOR CROHN’S DISEASES
8.5.4. INJECTABLE DRUGS FOR PSORIASIS
8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES

8.6. ORPHAN DISEASE
8.7. OTHER APPLICATIONS

8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTABLE DRUGS FOR HEPATITIS C
8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA

9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN

10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM

11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS

12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY

13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

13.1. OVERVIEW
13.2. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.2.1. U.S. INJECTABLE DRUG DELIVERY MARKET
13.2.2. CANADA INJECTABLE DRUG DELIVERY MARKET
13.2.3. MEXICO INJECTABLE DRUG DELIVERY MARKET

13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET

13.3.1. GERMANY INJECTABLE DRUG DELIVERY MARKET
13.3.2. FRANCE INJECTABLE DRUG DELIVERY MARKET
13.3.3. UK INJECTABLE DRUG DELIVERY MARKET
13.3.4. ITALY INJECTABLE DRUG DELIVERY MARKET
13.3.5. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.6. SPAIN INJECTABLE DRUG DELIVERY MARKET
13.3.7. NETHERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.8. RUSSIA INJECTABLE DRUG DELIVERY MARKET
13.3.9. TURKEY INJECTABLE DRUG DELIVERY MARKET
13.3.10. BELGIUM INJECTABLE DRUG DELIVERY MARKET
13.3.11. REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET

13.4. APAC INJECTABLE DRUG DELIVERY MARKET

13.4.1. JAPAN INJECTABLE DRUG DELIVERY MARKET
13.4.2. CHINA INJECTABLE DRUG DELIVERY MARKET
13.4.3. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET
13.4.4. INDIA INJECTABLE DRUG DELIVERY MARKET
13.4.5. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET
13.4.6. SINGAPORE INJECTABLE DRUG DELIVERY MARKET
13.4.7. THAILAND INJECTABLE DRUG DELIVERY MARKET
13.4.8. MALAYSIA INJECTABLE DRUG DELIVERY MARKET
13.4.9. INDONESIA INJECTABLE DRUG DELIVERY MARKET
13.4.10. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET
13.4.11. REST OF APAC INJECTABLE DRUG DELIVERY MARKET

13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.5.1. BRAZIL INJECTABLE DRUG DELIVERY MARKET
13.5.2. REST OF SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.6. MEA INJECTABLE DRUG DELIVERY MARKET

13.6.1. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET
13.6.2. REST OF MEA INJECTABLE DRUG DELIVERY MARKET

14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE

14.1. COMPANY SHARE ANALYSIS: GLOBAL

15. COMPANY PROFILES

15.1. BECTON, DICKINSON AND COMPANY

15.1.1. COMPANY OVERVIEW
15.1.1.1. DRIVERS EXPLAINED
15.1.1.2. WEAKNESSES EXPLAINED
15.1.1.3. OPPURTUNITIES EXPLAINED
15.1.1.4. THREATS EXPLAINED
15.1.2. PRODUCT PORTFOLIO
15.1.3. RECENT DEVELOPMENTS

15.2. PFIZER

15.2.1. COMPANY OVERVIEW
15.2.1.1. DRIVERS EXPLAINED
15.2.1.2. WEAKNESSES EXPLAINED
15.2.1.3. OPPURTUNITIES EXPLAINED
15.2.1.4. THREATS EXPLAINED
15.2.2. PRODUCT PORTFOLIO
15.2.3. RECENT DEVELOPMENTS

15.3. BAXTER INTERNATIONAL

15.3.1. COMPANY OVERVIEW
15.3.1.1. DRIVERS EXPLAINED
15.3.1.2. WEAKNESSES EXPLAINED
15.3.1.3. OPPURTUNITIES EXPLAINED
15.3.1.4. THREATS EXPLAINED
15.3.2. PRODUCT PORTFOLIO
15.3.3. RECENT DEVELOPMENTS

15.4. GERRESHEIMER AG

15.4.1. COMPANY OVERVIEW
15.4.2. PRODUCT PORTFOLIO
15.4.3. RECENT DEVELOPMENTS
15.5. SCHOTT AG INC.
15.5.1. COMPANY OVERVIEW
15.5.2. PRODUCT PORTFOLIO
15.5.3. RECENT DEVELOPMENTS

15.6. ALKERMES INC.

15.6.1. COMPANY OVERVIEW
15.6.2. PRODUCT PORTFOLIO
15.6.3. RECENT DEVELOPMENTS

15.7. ANTARES PHARMA

15.7.1. COMPANY OVERVIEW
15.7.2. PRODUCT PORTFOLIO
15.7.3. RECENT DEVELOPMENTS

15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)

15.8.1. COMPANY OVERVIEW
15.8.2. PRODUCT PORTFOLIO
15.8.3. RECENT DEVELOPMENTS

15.9. ELCAM MEDICAL

15.9.1. COMPANY OVERVIEW
15.9.2. PRODUCT PORTFOLIO
15.9.3. RECENT DEVELOPMENTS

15.10. ELI LILLY AND COMPANY

15.10.1. COMPANY OVERVIEW
15.10.1.1. DRIVERS EXPLAINED
15.10.1.2. WEAKNESSES EXPLAINED
15.10.1.3. OPPURTUNITIES EXPLAINED
15.10.1.4. THREATS EXPLAINED
15.10.2. PRODUCT PORTFOLIO
15.10.3. RECENT DEVELOPMENTS

15.11. HASELMEIER

15.11.1. COMPANY OVERVIEW
15.11.2. PRODUCT PORTFOLIO
15.11.3. RECENT DEVELOPMENTS

15.12. MYLAN N.V.

15.12.1. COMPANY OVERVIEW
15.12.2. PRODUCT PORTFOLIO
15.12.3. RECENT DEVELOPMENTS

15.13. NOVO NORDISK

15.13.1. COMPANY OVERVIEW
15.13.2. PRODUCT PORTFOLIO
15.13.3. RECENT DEVELOPMENTS

15.14. OWEN MUMFORD LTD

15.14.1. COMPANY OVERVIEW
15.14.2. PRODUCT PORTFOLIO
15.14.3. RECENT DEVELOPMENTS

15.15. SANDOZ INTERNATIONAL GMBH

15.15.1. COMPANY OVERVIEW
15.15.2. PRODUCT PORTFOLIO
15.15.3. RECENT DEVELOPMENTS

15.16. SANOFI

15.16.1. COMPANY OVERVIEW
15.16.2. PRODUCT PORTFOLIO
15.16.3. RECENT DEVELOPMENTS

15.17. TERUMO CORPORATION

15.17.1. COMPANY OVERVIEW
15.17.2. PRODUCT PORTFOLIO
15.17.3. RECENT DEVELOPMENTS

15.18. TEVA PHARMACEUTICAL

15.18.1. COMPANY OVERVIEW
15.18.1.1. DRIVERS EXPLAINED
15.18.1.2. WEAKNESSES EXPLAINED
15.18.1.3. OPPURTUNITIES EXPLAINED
15.18.1.4. THREATS EXPLAINED
15.18.2. PRODUCT PORTFOLIO
15.18.3. RECENT DEVELOPMENTS

15.19. WEST PHARMACEUTICAL SERVICES, INC

15.19.1. COMPANY OVERVIEW
15.19.2. PRODUCT PORTFOLIO
15.19.3. RECENT DEVELOPMENTS

15.20. YPSOMED HOLDING AG

15.20.1. COMPANY OVERVIEW
15.20.2. PRODUCT PORTFOLIO
15.20.3. RECENT DEVELOPMENTS

16. RELATED REPORTS

Browse Full Report @ http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com

This release was published on openPR.